Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study

Glioblastoma is the most common and aggressive primary brain tumor. Despite standard multimodality therapy, median overall survival remains poor with a 5-year survival rate of approximately 5% in most studies (range 4.7–13.0%). Strong interest in targeting IDH mutations has led to a variety of studi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:CNS Oncol
Huvudupphovsmän: Tejera, Dalissa, Kushnirsky, Marina, Gultekin, Sakir H, Lu, Min, Steelman, Lori, de la Fuente, Macarena I
Materialtyp: Artigo
Språk:Inglês
Publicerad: Future Medicine Ltd 2020
Ämnen:
Case Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7546125/
https://ncbi.nlm.nih.gov/pubmed/32716208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2020-0014
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk